In recent years, a concerning medical condition known as cannabis hyperemesis syndrome (CHS) has gained attention in the United States as recreational marijuana use becomes more prevalent. This syndrome, often informally referred to as 'scromiting' due to its painful symptoms, presents with severe abdominal pain, intense nausea, and recurrent vomiting, which can be debilitating for those affected. Medical experts explain that as the THC concentration in cannabis has increased significantly over the past couple of decades, many long-term users are experiencing worsening symptoms that mirror those typically treated with marijuana, leading to confusion among patients and healthcare professionals alike. Dr. Sam Wang, a pediatric emergency medicine specialist at Children's Hospital Colorado, has reported treating numerous minors suffering from CHS, stating that patients often exhibit signs of extreme distress while battling the effects of this syndrome. The condition is not only distressing but can also be life-threatening if left untreated; it can result in severe electrolyte imbalances, shock, and even organ failure. When hospitalized, patients typically receive IV fluids and antiemetic medications to manage their symptoms effectively. Experts note that while not every chronic marijuana user experiences CHS, the growing trend does raise significant health concerns. An alarming 2020 study indicated that between 2005 and 2014, approximately 20% of individuals hospitalized due to severe vomiting were using marijuana. This statistic, in conjunction with findings from a study published by Dr. Wang and colleagues in 2021, suggests that the legalization of marijuana in states such as Colorado correlates with an increase in CHS cases among patients seeking emergency medical care. The implications of these findings necessitate a broader discussion about the health impacts of legal and accessible marijuana across the U.S. As recreational marijuana laws continue to evolve, public health officials warn of the potential dangers associated with excessive usage. The increase in THC levels in cannabis products, now averaging 15-20%, has prompted some experts to consider this a significant factor in the uptick of CHS. Since the treatment for this syndrome requires complete cessation of marijuana use for effective recovery, patients are faced with difficult choices about their health. The rising incidence of cannabis hyperemesis syndrome underscores the need for continued education about the risks linked to frequent marijuana consumption, especially in contexts where it has become socially accepted and legal.

Cannabis hyperemesis syndrome (CHS) is a paradoxical condition that occurs in some individuals who consume cannabis regularly. Despite the well-known antiemetic properties of cannabis, this syndrome is characterized by recurrent episodes of severe nausea and vomiting, abdominal pain, and compulsive bathing behavior, often in hot water. The symptoms typically emerge after prolonged use of cannabis, and they tend to diminish upon cessation of consumption. As the popularity of cannabis has grown, particularly with the legalization in various regions, the medical community has noted an increase in cases of CHS, making it a critical topic of research and awareness for both patients and healthcare providers. The pathophysiology of cannabis hyperemesis syndrome remains poorly understood, but it is hypothesized that chronic exposure to cannabinoids may lead to dysregulation of the endocannabinoid system, which plays a pivotal role in gastrointestinal function and nausea control. In particular, the activation of CB1 receptors in the brain and GI tract might contribute to the onset of symptoms in susceptible individuals. Some researchers also point to the possibility of genetic predisposition or prior gastrointestinal disorders as contributing factors that can exacerbate CHS among regular cannabis users. Identifying these underlying mechanisms is crucial for developing effective treatment and management strategies for those affected by the syndrome. Patients suffering from CHS often find relief from their debilitating symptoms through non-cannabinoid interventions. Treatment typically involves supportive care and hydration, with many affected individuals responding positively to hot showers or baths as a temporary measure to alleviate nausea. In contrast, antiemetics that are commonly used may not always be effective in managing CHS symptoms. The definitive way to treat the syndrome is through the complete cessation of cannabis use, which usually leads to a cessation of symptoms within days to weeks. Education and awareness among healthcare providers are essential for timely diagnosis and management, as the syndrome can frequently be misdiagnosed as other gastrointestinal issues such as cyclic vomiting syndrome or gastroparesis. The rising incidence of cannabis hyperemesis syndrome underscores the need for continued research into the long-term effects of cannabis use, particularly in populations that are increasingly turning to cannabis for both medicinal and recreational purposes. As more jurisdictions legalize cannabis, it is imperative for public health campaigns to inform users of the potential risks associated with heavy and prolonged use. Future studies should aim to elucidate the biochemical pathways involved in CHS, potential genetic factors that predispose individuals to this syndrome, and the societal impact of cannabis consumption trends on public health.